Cumberland Pharmaceuticals Hits New 52-Week High of $7.21

Cumberland Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 7.21 on July 1, 2026. This achievement marks a remarkable increase in the stock's performance, reflecting a 402.11% rise over the past year, significantly outpacing the S&P 500's performance of 20.74% during the same period. As a microcap company in the Pharmaceuticals & Biotechnology industry, Cumberland Pharmaceuticals has a market capitalization of USD 46 million. Despite its recent stock performance, the company remains in a loss-making position, with a negative return on equity of -11.00%. The stock's price-to-book ratio stands at 1.85, indicating its valuation relative to its assets. The company's debt-to-equity ratio is reported at -0.23, suggesting a unique financial structure. With no dividend yield currently offered, Cumberland Pharmaceuticals continues to focus on its growth trajectory within the competitive pharmaceutical landscape. The achievement of this 52-week high underscores the stock's notable activity and performance in the market.